Rep. Cuellar Announces Lower Prescription Drug Costs

Dr. Cuellar Voted to Pass the Inflation Reduction Act (IRA), Which Enabled Negotiations to Lower Costs for Prescription Drugs Under Medicare

Translate to Spanish or other 102 languages!

Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
- Advertisement -

Washington, DC – Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare.

“I voted to pass the IRA, which has lowered health care and prescription drug costs for Americans. It not only capped the monthly cost of insulin for seniors on Medicare at $35 but also limited out-of-pocket prescription drug costs for seniors,” said Dr. Cuellar, a senior member of the House Appropriations Committee. “Furthermore, due to the IRA, the administration was able to negotiate lower costs for ten of the most expensive prescription drugs under Medicare. This is a historic achievement and will bring needed relief to everyday Americans. I voted for the Inflation Reduction Act to ensure that Americans get the help they need. I will continue to support efforts to reduce health care costs.” 

The ten drugs negotiated down include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp.

- Advertisement -

Through the IRA, more than 100,000 Texans on Medicare are saving on average $441 per year through the insulin price cap alone.  It caps insulin costs at $35 per month for those on Medicare and limits out-of-pocket prescription drug costs to $2,000 per year.

1,323,430 Texans will save $400 per year on average through the IRA’s $2,000 out-of-pocket cap, which will begin in 2025.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

What Persistent Fatigue Might Be Telling You

Mega Doctor News CLEVELAND CLINIC - We’ve all had those days where we’re...

AMA Unveils New Initiative to Boost Nutrition Education Nationwide

The American Medical Association (AMA) is launching a nutrition education initiative to equip physicians and medical students with practical, evidence-based knowledge and tools to help patients live healthier lives.

DHR Health to Host Headache Symposium to Address Gap in Neurological Care, March 28th

In the United States, headaches remain a common health concern, affecting approximately one in six Americans. Migraines, a type of headache, are the second leading cause of years lived with disability nationwide.

Study Finds GLP‑1 Therapy Reduces Heart and Kidney Risks for Type 1 Diabetes Patients

People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and end-stage kidney disease without any increase in safety concerns, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
- Advertisement -